

HR 7537

Infectious Disease Therapies Research and Innovation Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Taxation

Introduced: Jul 9, 2020

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (Jul 9, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/7537>

Sponsor

Name: Rep. Kelly, Mike [R-PA-16]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

| Committee | Chamber | Activity | Date |
|--------------------------|---------|-------------|-------------|
| Ways and Means Committee | House | Referred to | Jul 9, 2020 |

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

| Bill | Relationship | Last Action |
|-----------|--------------|---|
| 116 HR 14 | Related bill | Nov 2, 2020: Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials. |

Summary (as of Jul 9, 2020)

Infectious Disease Therapies Research and Innovation Act of 2020

This bill exempts from the definition of *passive activity*, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines *specified medical research small business pass-thru entity* as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than \$1 million.

Actions Timeline

- **Jul 9, 2020:** Introduced in House
- **Jul 9, 2020:** Referred to the Subcommittee on Health.
- **Jul 9, 2020:** Referred to the House Committee on Ways and Means.